Privi Speciality Chemicals Ltd Q4 FY2022 Concall Summary

Key Takeaways

• A year of stabilization, not growth: FY22 volume was nearly flat at ~29,432 tons as a Mahad flood cost almost a month of sales, while two major capex projects were delayed by pandemic oxygen bans. Profit was further squeezed by ₹70–72 Cr of higher freight and coal costs.
• Q4 sequential decline was deliberate: Sales fell ~4.5% QoQ because management consciously restricted supplies to high-risk Latin American markets, European buyers turned cautious post-war, and a six-day system shutdown for Oracle-to-SAP migration reduced billing days.
• The capex payoff is imminent, but unproven: Camphor and Galaxmusk projects are expected to capitalize in Q1 FY23 with first revenue from July 2022, yet management wants to see these assets sweat before committing to the next capex cycle, and near-term EBITDA may dip despite higher sales.
• Balance sheet stretched to a historic point: Debt-to-equity crossed 1x for the first time, working capital borrowings doubled YoY to ~₹450 Cr, and inventory ballooned to ~₹562 Cr. Management expects normalization only by March 2023.
• What to watch next quarter: Whether July production starts on schedule, the pace of inventory unwind, and any margin impact as low-cost raw material inventory reverses and higher CST prices flow through from late May.

FY22 Performance: A Year of Absorbing Shocks

• Volume lost to flood: The Mahad factory closure of three to three-and-a-half weeks meant FY22 volumes reflect roughly 11 months of operations, not 12, holding full-year volume growth to ~0.32%.
• Capex delayed by oxygen bans: State government bans on industrial oxygen supply during the pandemic pushed back completion of the Camphor project at Mahad Unit 2 and the Galaxmusk project at Jhagadia Unit 6, deferring the revenue contribution those assets were meant to deliver in FY22.
• Input cost double-hit: Freight expenses rose ₹50 Cr YoY and coal expenses rose ~₹20–22 Cr YoY, directly compressing profit below what the topline would otherwise have supported.
• Inventory build-up was structural, not speculative: Inventory rose to ~₹562 Cr driven by (1) imported items with long lead times piling up because three projects were delayed, and (2) Goods In Transit swelling due to freight problems, vessel transshipment delays, and longer vessel gestation times.
• Working capital stretched the balance sheet: Borrowings on the working capital front increased because money is tied up across inventory, payables, and receivables, while global recessionary and inflationary trends made money harder to come by. Debt-to-equity crossed 1x for the first time in Privi's history.
• RM margin held through efficiency: Despite raw material price spikes, RM-to-sales margin held at ~59.6%–60% because yield improvements and R&D process enhancements offset cost increases.
• Finance cost rose with utilization: Finance cost reached ₹8.3 Cr in Q4 FY22 because working capital utilization doubled from ~₹200 Cr to ~₹450 Cr YoY, and term-loan interest on Galaxmusk and Camphor capex will begin hitting the P&L once CWIP is capitalized.

Narayan Iyer: "2021-2022 has been a year of stabilization and maintaining our volumes in the market in the tough times... Privi continues its zeal on performance and we have been able to post a very decent performance in this tough times."

Q4 FY22: The Deliberate Slowdown

• Conscious risk avoidance in LatAm: Management deliberately restricted supplies to Latin American markets, especially Argentina, which it described as "completely bankrupt" and "on the verge of a huge inflation," prioritizing balance-sheet safety over volume.
• European demand turned cautious: Post-war, European buyers reduced offtake and the spot market shifted to a wait-and-watch stance, contributing to the ~4.5% sequential sales decline.
• System migration cost six billing days: The company shut its systems six days early to migrate from Oracle to SAP, directly reducing Q4 sales volume.
• Price realization partially offset the volume dip: Calendar-year contract price increases of 5%–8% took effect from January 1, 2022, contributing ~6% higher average realization in Q4 versus the first nine months.
• CST supply was not disrupted: Privi held large CST inventory from Scandinavia, the US, and Canada, and port operations in the Baltic/Caspian region resumed, allowing shipments to flow without material production impact.

Narayan Iyer: "So we as in Privi have not been really affected because of the war as we have a good amount of inventory of the CST both from the Scandinavian countries as well as from US and Canada."

Capex Pipeline: The Inflection That Must Deliver

• Two large projects nearing the finish line: Camphor (Mahad Unit 2) and Galaxmusk (Jhagadia Unit 6) are expected to be completed and capitalized in Q1 FY23, with first revenue or sales starting from July 2022 onward.
• Prionyl has just started: A third project, Prionyl, has only just begun operations and will contribute to the new-product ramp.
• ~10,000 tons of new capacity coming online: The three new products together add roughly 10,000 tons of capacity, underpinning the FY23 volume growth target of 15%–18% toward ~35,000 tons.
• Revenue ramp is back-end loaded: Spot sales are possible in Q2 FY23, better revenue is expected from Q3, and the large part of revenue will come in Q4 when the company can participate in annual contracts for 2023, with a revenue spurt expected in that quarter.
• Management wants proof before the next round: Privi may take a pause of 6–9 months to see how the new capex pans out before entering the next capex mode, and wants past capex of ₹500+ Cr to be "sweating in full flow" before raising fresh equity.
• Biotech is a 2025–26 story: Commercialization is expected in 2024–2025 with first revenue in 2025–2026, and capex for commercialization will take about a year to 15 months to set up after pilot success, but management cautioned that biotech timelines are inherently uncertain.

Narayan Iyer: "It is always better to raise the money when the company is really doing well and all past Capex's are actually sweating in full flow."

Margin Outlook: Near-Term Pain Before Steady-State Gain

• Low-cost inventory benefit will reverse: Higher CST prices from January dispatches will partially dent margins from late May onward, with most of the impact rolling into Q2 and Q3 FY23 as the company exhausts cheaper raw material inventory.
• Freight and energy costs remain elevated: The same freight and coal cost pressures that compressed FY22 profit are expected to persist, contributing to a near-term EBITDA that could remain flattish or even dip despite higher sales.
• Depreciation and interest will rise: Bottom line is likely to dip in the near term due to higher depreciation from capex commissioning and higher interest costs from elevated debt, with FY23 finance cost expected around ₹55 Cr.
• Steady-state margin target is 17.5%–19.5%: Once the situation stabilizes, management expects EBITDA margins to operate in this range, up from the normalized ~15.8% in FY22 (adjusting for ~₹25–30 Cr of operational forex income booked as other income).
• Debt-to-EBITDA expected to improve: From 3.82x in March 2022, management expects a decline to sub-3x by March 2023, driven by better EBITDA from new products, full-capacity sales of existing products, and some term-loan repayments.

Narayan Iyer: "It could remain a little flattish and probably there could be a dip too."

Demand & Growth: Cautiously Optimistic, Structurally Defensive

• Volume growth target of 15%–18% for FY23: Management expects to move from 29,432 tons toward ~35,000 tons, driven largely by the three new products starting production from July.
• ₹3,000 Cr topline vision stays, timeline may flex: The vision remains FY25; if conditions worsen, it may slip to FY26, but achieving ₹3,000 Cr is "for sure." A little bit of additional capex on existing pine-space products may be needed to reach that mark.
• Pipeline supports the next leg to ₹5,000 Cr: The company has about three or four products in the pipeline to take revenue from ₹3,000 Cr to ₹5,000 Cr, with R&D working on almost eight different products, and expects to add three or four new products in most years.
• Demand is structurally defensive, not immune: Management argued that 90% of products go into soaps, detergents, and fragrances, making them "to some extent recessionary proof," but acknowledged that specialty chemicals thrive on a feel-good factor in the global economy and the current negative trend could take three to six months to reverse.
• European gas risk is the wildcard: If the Ukraine-Russia stalemate continues, European countries could face a huge gas shortage, creating a difficult position for European companies and for Privi, which derives ~32% of revenue from Europe.
• CST sourcing is diversifying: The company is actively seeking more contracts from the US, Canada, and Southeast Asia/Brazil/Chile/Colombia for GTO to offset potential disruptions from Russian and Ukrainian mills.

Narayan Iyer: "We are a little cautiously optimistic in this year mainly because of the continuing pandemic situation, the war still not giving any sort of a trend of being completed or near completion because we still really do not know which way the war situation is going to pan about..."

Balance Sheet & Fundraise: Stretched Now, Equity Raise Ahead

• Inventory normalization is a 9–12 month journey: Inventory is expected to normalize by December 2022 and more so by March 2023, back to a factory level of ~2.5 months, with GIT inventory expected to remain at ~30 days and overall inventory days at ~105 to 110 days going forward.
• Cost of borrowing remains low at ~4.7%: A large portion of borrowings are in foreign currency at lower rates, and Indian banks offer competitive rates due to Privi's good credit rating and timely debt servicing.
• Board approved an enabling resolution for equity raise: The board approved a resolution to raise equity from the market for the next set of capex expansions and possibly to improve the balance sheet and reduce debt.
• Fundraise timeline is 6–9 months away: The entire process (board, shareholder, and stock exchange approvals, plus appointment of investment bankers) could take 6–9 months, comparable to running an IPO, and management wants to see returns from existing capex before coming to the market.
• Dilution could be up to 10–12%: Management offered that dilution could be less than or equal to 10%–12% of equity, but said it is too early to estimate the quantum precisely.

Guidance & Commitments

Key Metrics